Satellos Bioscience Inc. MSLE
Set alert
6.70 USD -0.12 -1.69%
At close · Oct 30
6.82 +0.12 +1.79%
After hours · Oct 30, 4:00 PM ET
6.43 Day range 6.93
5.59 52-week range 13.01
- YTD
- +13.95%
- 1 year
- +3.08%
- Open
- 6.68
- Prev close
- 6.82
- Mkt cap
- 142.15M
- Vol
- 30.78K
- Avg vol
- 42.12K
- EPS
- -1.95
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.43
- High
- 6.93
3M chart
Signals (22)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 4 days ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 2, 2026 | 1 month ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 3, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
Financials — quick view
MSLE Revenue — quarterly 0
MSLE Net income — quarterly -11.72M
MSLE EPS — quarterly -0.56
News
- Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
- Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
- Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age
- Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages
- FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy
- HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
- Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
- HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18
- Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
- Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Your note
Sign in to keep a note on MSLE — it syncs with the Stock Master app.